Emergent Biosolutions (NYSE:EBS) Downgraded by ValuEngine

Emergent Biosolutions (NYSE:EBS) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, ValuEngine reports.

Several other equities analysts also recently issued reports on EBS. Chardan Capital reaffirmed a “buy” rating and set a $71.00 price target on shares of Emergent Biosolutions in a research note on Thursday, November 7th. Guggenheim assumed coverage on shares of Emergent Biosolutions in a research note on Thursday, September 12th. They set a “buy” rating and a $65.00 price target for the company. TheStreet raised shares of Emergent Biosolutions from a “c” rating to a “b” rating in a research note on Wednesday, November 6th. Laidlaw set a $72.00 price target on shares of Emergent Biosolutions and gave the company a “buy” rating in a research note on Wednesday, September 4th. Finally, Wells Fargo & Co reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $69.00.

EBS stock opened at $54.71 on Thursday. The company has a fifty day moving average price of $54.25 and a 200-day moving average price of $48.11. The company has a market capitalization of $2.82 billion, a P/E ratio of 23.48, a PEG ratio of 0.89 and a beta of 1.55. Emergent Biosolutions has a 52-week low of $39.11 and a 52-week high of $73.89. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.71 and a current ratio of 2.54.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.58. The firm had revenue of $311.80 million during the quarter, compared to the consensus estimate of $289.16 million. Emergent Biosolutions had a net margin of 0.42% and a return on equity of 10.05%. The company’s revenue for the quarter was up 79.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.55 earnings per share. As a group, sell-side analysts forecast that Emergent Biosolutions will post 3.03 earnings per share for the current fiscal year.

In related news, Director Kathryn C. Zoon sold 3,082 shares of Emergent Biosolutions stock in a transaction on Friday, November 8th. The shares were sold at an average price of $54.15, for a total transaction of $166,890.30. Following the completion of the transaction, the director now owns 18,412 shares of the company’s stock, valued at $997,009.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Kathryn C. Zoon sold 1,509 shares of Emergent Biosolutions stock in a transaction on Monday, September 9th. The stock was sold at an average price of $56.12, for a total transaction of $84,685.08. Following the transaction, the director now directly owns 21,494 shares of the company’s stock, valued at approximately $1,206,243.28. The disclosure for this sale can be found here. 14.10% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in EBS. Fisher Asset Management LLC grew its holdings in Emergent Biosolutions by 23.3% in the second quarter. Fisher Asset Management LLC now owns 657,957 shares of the biopharmaceutical company’s stock worth $31,786,000 after purchasing an additional 124,413 shares during the period. Marshall Wace LLP acquired a new stake in Emergent Biosolutions in the second quarter worth $3,638,000. Vaughan Nelson Investment Management L.P. grew its holdings in Emergent Biosolutions by 8.3% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 571,409 shares of the biopharmaceutical company’s stock worth $27,605,000 after purchasing an additional 44,009 shares during the period. Rhumbline Advisers grew its holdings in Emergent Biosolutions by 0.6% in the third quarter. Rhumbline Advisers now owns 136,787 shares of the biopharmaceutical company’s stock worth $7,151,000 after purchasing an additional 775 shares during the period. Finally, Susquehanna International Group LLP grew its holdings in Emergent Biosolutions by 272.5% in the second quarter. Susquehanna International Group LLP now owns 58,115 shares of the biopharmaceutical company’s stock worth $2,808,000 after purchasing an additional 42,515 shares during the period. 87.98% of the stock is owned by institutional investors and hedge funds.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

See Also: G-20

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.